AbCellera, tapped by Lilly for its COVID-19 antibody therapy, sets IPO terms with $5B valuation

Canada’s speedy R&D engine AbCellera, now world-renowned for its tech producing the Eli Lilly COVID-19 drug authorized by the FDA, has set terms for a monster IPO.